Gradually divest the real estate and strengthen the company's determination to transform medical and health care.
The company announced on the evening of December 1 that it would sell some of its real estate business and get nearly 500 million in cash, which strengthened the company's determination to transform its medical and health care and provided a solid financial backing for the company to lay out its medical sector business. at the same time, the company announced the acquisition of 65% of the hospital in Anhui Lu'an Development Zone, which continued to accelerate the layout of the company's whole tumor business chain. In addition, the company also announced that it had obtained the exclusive patent right of leonurine, a national first-class new drug, from Fudan University, which injected power into the company's sustainable development in the medical sector and built a professional tumor ecological management platform in an all-round way.
Through the acquisition of all-in-one Healthcare, the company will make full use of its years of accumulation in the field of oncology services, fully involved in the whole value chain of oncology services, including early tumor screening (liver cancer-liver cirrhosis ultrasound detector, breast cancer-phased array radar breast imaging system): popularize the equipment to various scenes of residents' lives. To meet its long-term suppressed demand for early tumor monitoring in a cheaper, more convenient and more effective way, to help it achieve self-health management, but also to enter the C-end of the card. Tumor treatment: create a medical couplet with the Zhong Zhu brand (characterized by radiotherapy, supplemented by surgery, drugs and other cutting-edge treatments). Focus on liver cancer, breast cancer and other areas of cancer diseases that can be linked with the company's tumor detection service system) and tumor rehabilitation (combined with real estate).
Capital helps the company to accelerate the layout of the whole business chain of tumor.
This year, with the help of capital, the company has made rapid progress in the layout of the whole tumor business chain: in terms of tumor screening equipment, nearly 400 ultrasound detectors for liver cirrhosis have been sold in the first three quarters (240 in 2015), and more than 700 have been sold in the whole year. Next year, it will continue to maintain growth of about 100%. The phased array radar breast imaging system (which is likely to be the first in the world) is progressing smoothly and is expected to be listed in 2018. In the aspect of oncology medicine: there are still 28 treatment centers in the company's military system, and this year the company has signed 4 new tumor treatment centers (3 will open this year) and 2 hospitals. The company plans to land 100 tumor treatment centers and 30 specialist oncology hospitals in about three years. The follow-up company will continue to use capital to accelerate the layout of the whole business chain of the company.
And won the exclusive patent right of the national class 1 new drug-motherwort.
Motherwort alkaloid project is the research achievement of Zhu Yili, a scholar of the Yangtze River, the first expert of the National 973 Program and a professor of Fudan University. It has been established by the national "major new drug creation" science and technology projects "Eleventh five-year Plan" and "Twelfth five-year Plan". At present, it has been proved to have obvious curative effect on lipid reduction and treatment of cerebral stroke (inhibiting inflammation of atherosclerotic plaque and reducing the area of cerebral cortex infarction caused by cerebral ischemia). In the follow-up, China-Pearl will accelerate the listing of this product and inject impetus into the sustainable development of the company's medical sector.
Profit forecast and investment suggestion
Considering that the date of the real estate divestiture has not yet been determined, the performance of the temporary maintenance company in 2016-2018 is 353 million yuan, 517 million yuan and 705 million yuan respectively (153 million, 317 million and 505 million yuan contributed by the medical sector), and the corresponding EPS is 0.50,0.73 and 0.99 respectively. The company's subsequent extension is expected to be strong. And from major shareholders (private equity exchangeable debt for stock exchange cost 26.75 yuan), chairman, core executives, middle-level employees and all-in-one medical chairman and core executives are optimistic about the future development of the company, through fixed increase (650 million yuan, participate in 50% focus 17.48 yuan), increase holdings, employee stock ownership plan (890 million yuan, employee 185 million, cost 17.98 yuan Take into account the leverage cost of 19.10 yuan), mergers and acquisitions for stock swap (14.53 yuan for all shares in one Healthcare, the ban will be lifted in February next year) and other ways to firmly acquire the company's stock to demonstrate confidence and maintain the "buy" rating.
Risk hint: the progress of business promotion is lower than expected, and the progress of M & An is lower than expected.